P2 Purinergic Receptors in Tumor Immunity

Abstract P2 purinergic receptors are activated by extracellular ATP and other nucleotides released during cellular stress, hypoxia, or inflammation, serving as key mediators of intercellular communication. In cancer, they rapidly accumulate in the tumor microenvironment following cell death or metabolic stress. Activation of the P2 purinergic receptors P2X and P2Y can trigger both proinflammatory and immunosuppressive responses, and emerging evidence underscores P2 purinergic signaling as a central immunomodulator in cancer, critically shaping tumor immunobiology by coordinating immune cell interactions. This review explores how P2 purinergic signaling drives tumor progression through microenvironmental cross-talk and highlights therapeutic strategies targeting the pathway to disrupt protumorigenic networks.